stemcellcure | Arkansas news, politics, opinion, restaurants, music, movies and art

Member since Mar 5, 2011

Favorite Places

  • None.
Find places »

Saved Events

  • Nada.
Find events »

Saved Stories

  • Nope.
Find stories »

Custom Lists

  • Zip.


  • No friends yet.
Become My Friend Find friends »


Recent Comments

Re: “Talking the talk in the 3rd District

Entitlements need to go. People will be living dramatically longer lives and entitlements are simply unsustainable. Cephalon is leading the charge in the new wave of "biological drugs". PII results just published in Nature showed that Cephalon's "off-the-shelf" stem cell drug Revascor reduced MACE (Major Adverse Cardiac Events: chest pain, heart attack, death, etc) by an unprecedented 84%, virtually curing heart disease with a single injection. If you can afford it, the drug has been approved for treatment in Australia. Even though they just beat earnings, raised EPS targets, are net positive cash and have the highest FCF/share of any biotech, Cephalon is approaching a 52-week low and has the highest short interest of any stock in the S&P 500. Go figure.

Posted by stemcellcure on 03/05/2011 at 4:52 PM


© 2018 Arkansas Times | 201 East Markham, Suite 200, Little Rock, AR 72201
Powered by Foundation